First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
"The A rating from MSCI is a significant recognition of our improvement in ESG performance," said Sherry Shao, Rotating CEO of GenScript. "We believe that ...
First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...
Dizal (, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that th...
New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating the ultimate ...
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been s...
Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and ...
Dräger India is proud to announce the launch of the BabyRoo® TN 300 open warmer, with state-of-the-art thermoregulation capabilities as well as ad...
In an exclusive statement released through Guggenheim Securities, LLC, former Pfizer CEO Ian Read and former CFO Frank D’Amelio addressed growing s...
Note: Merck operates as MilliporeSigma in North America. Facility consolidates biosafety testing, analytical development, and cell bank manufact...
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with ne...
© 2024 Biopharma Boardroom. All Rights Reserved.
